欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (12): 1410-1413.

• 药物治疗学 • 上一篇    下一篇

参麦注射液对肿瘤化疗患者血常规和CD4/CD8比例的影响

周月芬, 吴敏华, 陈旭烽, 应筱莉, 谢艳茹, 王永辉, 楼建   

  1. 温州医学院附属第五医院丽水市中心医院肿瘤内科,丽水 323000,浙江
  • 收稿日期:2011-10-05 修回日期:2011-11-11 出版日期:2011-12-26 发布日期:2012-01-07
  • 作者简介:周月芬,本科,主任中医师,研究方向:以生物靶标检测为基础的常见恶性肿瘤个体化化疗和分子靶向治疗。Tel: 0578-2681217 E-mail: zjls2003@tom.com

Effection of Shenmai Injection for chemotherapy patients with cancer on blood tests and CD4/CD8 ratio

ZHOU Yue-fen , WU Min-hua, CHEN Xue-feng, YIN Xiao-li , XIE Yan-ru, WANG Yong-hui, LOU Jian   

  1. Oncology Department, the 5th Affiliated Hospital of Wenzhou Medical College ,the Central Hospital of Lishui City, Lishui 323000, Zhejiang, China
  • Received:2011-10-05 Revised:2011-11-11 Online:2011-12-26 Published:2012-01-07

摘要: 目的: 观察参麦注射液对消化道肿瘤术后化疗病人的血常规及CD4/CD8的影响。方法: 80例消化道肿瘤术后病人,随机分为单纯化疗组,参麦+化疗组,每组40例,两组均予含奥沙利铂3周方案化疗。单纯化疗组不加保护剂;参麦+化疗组每次化疗期间连用参麦注射液50 mL/d,共5 d。比较两组病人6疗程化疗后外周血中性粒细胞、中医症状积分的平均值;对比两组病人CD4/CD8绝对值及比例情况。结果: 参麦+化疗组化疗后中性粒细胞、CD4/CD8比例较单纯化疗组高,有统计学差异(P<0.05);单纯化疗组化疗后中医症状积分较参麦+化疗组高,两组有统计学差异(P<0.01)。结论: 参麦注射液能改善化疗相关症状,减轻化疗骨髓抑制,调节化疗患者免疫状态,保证化疗顺利进行。

关键词: 参麦注射液, 肿瘤, 血常规, CD4/CD8

Abstract: AIM: To study the effect of Shenmai Injection for gastrointestinal tumor patients after operation with oxaliplatin chemotherapy on blood tests and CD4/CD8 level.METHODS: Eighty cases of gastrointestinal tumor patients after operation with oxaliplatin chemotherapy were divided into single group and combined group, each 40 cases. The single group was administered by chemotherapy only while the combined group by chemotherapy and Shenmai Injection. After 6 cycle chemotherapy, TCM symptoms integral, neutrophils, CD4/CD8 ratio were compared between two groups.RESULTS: Compared with the single group, the TCM symptoms integral of the combined group was less (P<0.01). Compared with the single group, the neutrophils level of the combined group was less (P<0.05). Compared with the single group, the CD4 level and CD4/CD8 ratio were more and statistically significant (P<0.05).CONCLUSION: Shenmai Injection can improve chemotherapy related symptoms and reduce bone marrow toxicity; it can also adjust chemotherapy patient's immune status and ensure chemotherapy smoothly.

Key words: Shenmai Injection, Tumor, Blood routine, CD4/CD8

中图分类号: